Immunome Inc.

6.71
0.45 (7.19%)
At close: Apr 02, 2025, 3:59 PM
6.68
-0.37%
After-hours: Apr 02, 2025, 05:20 PM EDT

Immunome Statistics

Share Statistics

Immunome has 86.95M shares outstanding. The number of shares has increased by 44.99% in one year.

Shares Outstanding 86.95M
Shares Change (YoY) 44.99%
Shares Change (QoQ) 39.31%
Owned by Institutions (%) 88.55%
Shares Floating 75.42M
Failed to Deliver (FTD) Shares 5.1K
FTD / Avg. Volume 0.48%

Short Selling Information

The latest short interest is 10.54M, so 16.89% of the outstanding shares have been sold short.

Short Interest 10.54M
Short % of Shares Out 16.89%
Short % of Float 20.55%
Short Ratio (days to cover) 12.51

Valuation Ratios

The PE ratio is -2.13 and the forward PE ratio is -3.53. Immunome's PEG ratio is 0.3.

PE Ratio -2.13
Forward PE -3.53
PS Ratio 68.88
Forward PS 1.8
PB Ratio 3.44
P/FCF Ratio -5.28
PEG Ratio 0.3
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Immunome.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.03.

Current Ratio 4.08
Quick Ratio 4.08
Debt / Equity 0.03
Debt / EBITDA -0.03
Debt / FCF -0.04
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $76.62K
Profits Per Employee $-2.48M
Employee Count 118
Asset Turnover 0.04
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -70.73% in the last 52 weeks. The beta is 1.94, so Immunome's price volatility has been higher than the market average.

Beta 1.94
52-Week Price Change -70.73%
50-Day Moving Average 9.35
200-Day Moving Average 12.03
Relative Strength Index (RSI) 26.66
Average Volume (20 Days) 1.07M

Income Statement

In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.

Revenue 9.04M
Gross Profit 9.04M
Operating Income -305.8M
Net Income -292.96M
EBITDA -151.35M
EBIT -153.46M
Earnings Per Share (EPS) -5
Full Income Statement

Balance Sheet

The company has 143.35M in cash and 4.83M in debt, giving a net cash position of 138.52M.

Cash & Cash Equivalents 143.35M
Total Debt 4.83M
Net Cash 138.52M
Retained Earnings -515.77M
Total Assets 240.24M
Working Capital 167.03M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -110.79M and capital expenditures -7.17M, giving a free cash flow of -117.97M.

Operating Cash Flow -110.79M
Capital Expenditures -7.17M
Free Cash Flow -117.97M
FCF Per Share -2.01
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -3382.37% and -3240.38%.

Gross Margin 100%
Operating Margin -3382.37%
Pretax Margin -3240.38%
Profit Margin -3240.38%
EBITDA Margin -1674.08%
EBIT Margin -3382.37%
FCF Margin -1304.8%

Dividends & Yields

IMNM does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for IMNM is $25, which is 299.4% higher than the current price. The consensus rating is "Buy".

Price Target $25
Price Target Difference 299.4%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score 1.25
Piotroski F-Score 2